Free Base vs. Acetate: Why the FDA Reviews Each Peptide Salt Form Separately at the July 2026 PCAC

According to the Federal Register notice published April 16, 2026 (reported as 91 FR 20465, Document 2026-07361), the FDA opened public docket FDA-2025-N-6895 and listed each candidate peptide as two distinct bulk drug substances — for example, 'BPC-157 (free base)' and 'BPC-157 acetate.' This is not a clerical duplication. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, the Bulk Drug Substances List names specific active pharmaceutical ingredients eligible for compounding. A free base and its acetate salt are different chemical entities: they have different molecular formulas, different molecular weights, different solubility, and potentially different stability and impurity profiles.

Because the 503A list is built through notice-and-comment rulemaking, the FDA must define precisely which substance it is evaluating. The nomination package, the supporting data, and any findings attach to a specific form. A favorable review of the acetate salt would not automatically extend to the free base, and vice versa — so the agency treats each as its own line item with its own evidentiary record.

Per the FDA advisory-committee calendar, the Pharmacy Compounding Advisory Committee meets July 23-24, 2026 at the FDA White Oak Campus in Silver Spring, Maryland. Day one covers BPC-157, KPV, TB-500, and MOTS-C; day two covers Emideltide (DSIP), Semax, and Epitalon. According to RAPS, a second PCAC meeting before the end of February 2027 is expected to address five additional peptides, for twelve in total. The Federal Register notice states that comments received on or before July 9, 2026 are provided to the committee, and that the docket closes July 22, 2026.

For each peptide, the agenda lists both the free base and the acetate salt as separate nominations. The nomination materials also pair a substance with a specific compounded use being put forward for review — for instance, the BPC-157 acetate nomination is associated with ulcerative colitis as the compounded use under consideration. That is reported here strictly as the nominator's stated use under regulatory review; it is not a use recommendation, an approved indication, or a statement about effects. PCAC recommendations are advisory and non-binding; the FDA decides afterward whether to proceed toward placement on the 503A list through formal rulemaking.

A peptide synthesized and purified in the laboratory does not exist as a neutral free base in isolation. Basic side chains (lysine, arginine, histidine) and the free N-terminus carry positive charge, and that charge is balanced by a counterion. When the counterion is acetate (CH3COO-, molecular weight roughly 60 g/mol), the isolated solid is an acetate salt. When it is trifluoroacetate (TFA), it is a TFA salt. The free base form, by contrast, is the deprotonated peptide without an associated acid counterion.

The counterion is not inert packaging. According to manufacturer technical guidance, salt form measurably affects solubility, hygroscopicity, crystallinity, and aggregation behavior, which is why salt selection is a standard formulation decision in peptide development. In later-stage manufacturing, acetate is often selected over TFA and chloride because it avoids residual TFA, which can interfere with downstream analysis. Converting between salt forms requires an additional ion-exchange step, so the form on the label reflects a deliberate manufacturing choice rather than an accident of synthesis.

The single most important consequence for a researcher weighing material is net peptide content (NPC). NPC is the percentage of the solid mass that is actually peptide, as opposed to counterions, residual moisture, and other salts. Crucially, NPC is not the same as chromatographic purity. A peptide can be 99% pure by HPLC peak area yet have a net peptide content well below 100%, because purity describes the fraction of peptide-related material that is the target sequence, while NPC describes how much of the total weighed solid is peptide at all.

Salt form is a primary driver of NPC. Acetate and TFA add mass that is not peptide; a peptide rich in basic residues forms more salt and therefore carries a lower NPC even when extremely pure. Two vials labeled '10 mg' — one an acetate salt, one a different salt or a free base — can contain different actual masses of the peptide. Reading the salt-corrected net peptide content, not just the gross fill weight, is what makes two products comparable on a like-for-like basis.

• Purity (HPLC, UV at 210-220 nm): fraction of peptide-related material that is the target sequence.
• Net peptide content: fraction of the total weighed solid that is peptide, after subtracting counterions and moisture.
• Counterion content: acetate measured by HPLC or ion chromatography; residual TFA measured by ion chromatography.
• Molecular weight: confirmed by mass spectrometry; the salt's nominal MW differs from the free base by the counterion mass.

A certificate of analysis should make the salt form explicit and report the parameters that the salt form affects. When the COA names the substance, it should state whether the material is a free base, acetate, or TFA salt — the same distinction the FDA is drawing on its 503A agenda. The mass spectrometry result should match the expected monoisotopic or average mass of the free peptide; the salt mass is generally not reflected in the MS peak, which is why MS confirms sequence identity but does not by itself tell you the salt form.

To establish how much peptide is present, the COA should report net peptide content (or peptide content by quantitative amino acid analysis or nitrogen analysis) alongside HPLC purity, water content (Karl Fischer), and a counterion assay. A COA that lists only a single 'purity' number and omits salt form, counterion content, and net peptide content leaves the actual peptide mass per vial undefined — even if that single number is high.

According to legal analyses of the docket, the July 2026 review follows the FDA's 2023 placement of more than a dozen peptides into Category 2 — substances for which the agency identified safety concerns, citing immunogenicity, peptide-related impurities, and complexities in characterizing the active ingredient. The PCAC process now revisits whether specific forms of these peptides have sufficient supporting data to be considered for the 503A list (the framework the FDA describes as Category 1), with Category 3 reserved for nominations lacking enough information to evaluate.

Treating each salt form separately is consistent with that emphasis on precise active-ingredient characterization: the agency is evaluating defined chemical entities, with defined molecular weights and counterions, against defined evidentiary standards. None of this changes the research-use-only status of these materials; placement on a 503A compounding list is a separate regulatory pathway from how research peptides are supplied and labeled for laboratory work.

Because BPC-157 (free base) and BPC-157 acetate are distinct chemical entities with different molecular weights, counterions, and stability profiles. The Section 503A Bulk Drug Substances List names specific active pharmaceutical ingredients, so the FDA evaluates each salt form as its own nomination with its own data record under docket FDA-2025-N-6895.

The free base is the deprotonated peptide with no associated acid counterion. The acetate salt is the same peptide sequence paired with acetate counterions (roughly 60 g/mol each) that balance the peptide's positive charges. The sequence is identical, but molecular weight, solubility, hygroscopicity, and net peptide content differ.

No. HPLC purity describes the fraction of peptide-related material that is the target sequence, not the fraction of the total solid that is peptide. Net peptide content accounts for counterions and moisture, so a 99%-pure acetate salt can have a net peptide content noticeably below 99% — particularly for sequences rich in basic amino acids.

A complete certificate of analysis should state the salt form explicitly and report net peptide content, HPLC purity, mass spectrometry, water content, and a counterion assay (acetate or residual TFA). If only a single purity number is given with no salt form or net peptide content, the actual peptide mass per vial is undefined.

No. PCAC recommendations are advisory and non-binding. After the meeting, the FDA decides whether to proceed toward 503A list placement through formal notice-and-comment rulemaking, a separate process. The advisory vote does not change the research-use-only status of these materials.

Generally no. The MS peak reflects the mass of the peptide itself, confirming sequence identity, but the counterion typically does not appear in the measured mass. Salt form is established by the substance designation and a counterion assay (HPLC or ion chromatography), not by the mass spectrum alone.

• FDA Peptide Reclassification 2026: 14 Peptides Return to Category 1 -> /learn/fda-peptide-reclassification-2026-14-peptides-return-to-category-1
• Are Research Peptides Legal? -> /learn/are-research-peptides-legal
• Research Use Only (RUO) Legal Status for Peptides: Complete Guide -> /learn/research-use-only-ruo-legal-status-for-peptides-complete-guide
• Verify a Certificate of Analysis -> /verify
• Compare Peptide Sources and Pricing -> /compare